Patients with obsessive-compulsive disorder have increased 5-HT 2A receptor binding in the caudate nuclei

International Journal of Neuropsychopharmacology

Volumn 8, Issue 3, 2005, Pages 391-401

  Adams, Karen H ^a   Hansen, Elsebeth S ^a   Pinborg, Lars H ^a   Hasselbalch, Steen G ^a   Svarer, Claus ^a   Holm, Søren ^a   Bolwig, Tom G ^a   Knudsen, Gitte M ^a  

^a Mental Health Services CPH   (Denmark)

Author keywords

OCD; Positron emission tomography (PET); Serotonin 5 HT2A receptors

Indexed keywords

ALTANSERIN; CITALOPRAM; FLUOXETINE; PAROXETINE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ARTICLE; BRAIN; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RECEPTOR BINDING; FEMALE; HUMAN; MALE; MENTAL DISEASE; NEUROIMAGING; NEUROTRANSMISSION; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSESSIVE COMPULSIVE DISORDER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RATING SCALE; SEROTONINERGIC SYSTEM; SIDE EFFECT; TREATMENT OUTCOME; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; BRAIN MAPPING; CAUDATE NUCLEUS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; KETANSERIN; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RECEPTOR, SEROTONIN, 5-HT2A;

EID: 22344431815     PISSN: 14611457     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1461145705005055     Document Type: Article

References (52)

1. APA (1994). Diagnostic and Statistical Manual of Mental Disorders (4th edn). Washington, DC: American Psychiatric Press.
2. Arango V, Underwood MD, Mann JJ (1997). Postmortem findings in suicide victims. Implications for in vivo imaging studies. Annals of the New York Academy of Science 836, 269-287.
3. 2 binding sites in the frontal cortex of suicide victims and control subjects. American Journal of Psychiatry 146, 730-736.
4. Attar-Levy D, Martinet JL, Blin J, Dao-Castellana MH, Crouzel C, Mazoyer B, Poirier MF, Bourdel MC, Aymard N, Syrota A, Feline A (1999). The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine. Biological Psychiatry 45, 180-186.
5. Baxter Jr. LR, Phelps ME, Mazziotta JC, Guze BH, Schwartz JM, Selin CE (1987). Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls. Archives of General Psychiatry 44, 211-218.
6. Baxter Jr. LR, Schwartz JM, Bergman KS, Szuba MP, Guze BH, Mazziotta JC, Alazraki A, Selin CE, Ferng HK, Munford P, Phelps ME (1992). Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Archives of General Psychiatry 49, 681-689.
7. Baxter Jr. LR, Schwartz JM, Mazziotta JC, Phelps ME, Pahl JJ, Guze BH, Fairbanks L (1988). Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. American Journal of Psychiatry 145, 1560-1563.
8. Biver F, Lotstra F, Monclus M, Wikler D, Damhaut P, Mendlewicz J, Goldman S (1996). Sex difference in 5-HT2 receptor in the living human brain. Neuroscience Letters 204, 25-28.
9. Cottraux J, Note I, Yao SN, Lafont S, Note B, Mollard E, Bouvard M, Sauteraud A, Bourgeois M, Dartigues JF (2001). A randomized controlled trial of cognitive therapy versus intensive behavior therapy in obsessive-compulsive disorder. Psychotherapy and Psychosomatics 70, 288-297.
10. DeGrado TR, Turkington TG, Williams JJ, Stearns CW, Hoffman JM, Coleman RE (1994). Performance characteristics of a whole-body PET scanner. Journal of Nuclear Medicine 35, 1398-1406.
11. Delgado PL, Moreno FA (1998). Hallucinogens, serotonin and obsessive-compulsive disorder. Journal of Psychoactive Drugs 30, 359-366.
12. Eastwood SL, Burnet PW, Gittins R, Baker K, Harrison PJ (2001). Expression of serotonin 5-HT(2A) receptors in the human cerebellum and alterations in schizophrenia. Synapse 42, 104-114.
13. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS (1989). The Yale-Brown Obsessive-compulsive Scale. I. Development, use, and reliability. Archives of General Psychiatry 46, 1006-1011.
14. Hanes KR (1996). Serotonin, psilocybin, and body dysmorphic disorder: a case report. Journal of Clinical Psychopharmacology 16, 188-189.
15. Hansen ES, Hasselbalch S, Law I, Bolwig TG (2002). The caudate nucleus in obsessive-compulsive disorder. Reduced metabolism following treatment with paroxetine: a PET study. International Journal of Neuropsychopharmacology 5, 1-10.
16. Hollander E, DeCaria CM, Nitescu A, Gully R, Suckow RF, Cooper TB, Gorman JM, Klein DF, Liebowitz MR (1992). Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Archives of General Psychiatry 49, 21-28.
17. Hrdina PD, Demeter E, Vu TB, Sotonyi P, Palkovits M (1993). 5-HT uptake sites and 5-HT2 receptors in brain of antidepressant-free suicide victims/depressives: increase in 5-HT2 sites in cortex and amygdala. Brain Research 614, 37-44.
18. Insel TR (1992). Toward a neuroanatomy of obsessive-compulsive disorder. Archives of General Psychiatry 49, 739-744.
19. Jenike MA, Baer L, Summergrad P, Minichiello WE, Holland A, Seymour R (1990b). Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo. American Journal of Psychiatry 147, 923-928.
20. Jenike MA, Hyman S, Baer L, Holland A, Minichiello WE, Buttolph L, Summergrad P, Seymour R, Ricciardi J (1990a). A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. American Journal of Psychiatry 147, 1209-1215.
21. Karno M, Golding JM, Sorenson SB, Burnam MA (1988). The epidemiology of obsessive-compulsive disorder in five US communities. Archives of General Psychiatry 45, 1094-1099.
22. Lassen NA (1992). Neuroreceptor quantitation in vivo by the steady-state principle using constant infusion or bolus injection of radioactive tracers. Journal of Cerebral Blood Flow Metabolism 12, 709-716.
23. Lemaire C, Cantineau R, Guillaume M, Plenevaux A, Christiaens L (1991). Fluorine-18-altanserin: a radioligand for the study of serotonin receptors with PET: radiolabeling and in vivo biologic behavior in rats. Journal of Nuclear Medicine 32, 2266-2272.
24. Lewellen TK, Kohlmeyer SG, Miyaoka RS, Kaplan MS, Stearns CW, Schubert SF (1996). Investigation of the performance of the general electric ADVANCE positron emission tomograph in 3D mode. IEEE Transactions in Nuclear Science 43, 2199-2206.
25. Lindsay M, Crino R, Andrews G (1997). Controlled trial of exposure and response prevention in obsessive-compulsive disorder. British Journal of Psychiatry 171, 135-139.
26. McGuire PK, Bench CJ, Frith CD, Marks IM, Frackowiak RS, Dolan RJ (1994). Functional anatomy of obsessive-compulsive phenomena. British Journal of Psychiatry 164, 459-468.
27. Meltzer CC, Smith G, Price JC, Reynolds CF, Mathis CA, Greer P, Lopresti B, Mintun MA, Pollock BG, Ben-Eliezer D, Cantwell MN, Kaye W, Dekosky ST (1998). Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. Brain Research 813, 167-171.
28. Meyer JH, Kapur S, Eisfeld B, Brown GM, Houle S, DaSilva J, Wilson A, Rafi-Tari S, Mayberg H, Kennedy S (2001). The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. American Journal of Psychiatry 158, 78-85.
29. Moreno FA, Delgado PL (1997). Hallucinogen-induced relief of obsessions and compulsions. American Journal of Psychiatry 154, 1037-1038.
30. Moses EL, Drevets WC, Smith G, Mathis CA, Kalro BN, Butters MA, Leondires MP, Greer PJ, Lopresti B, Loucks TL, Berga SL (2000). Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biological Psychiatry 48, 854-860.
31. Pauls DL, Leckman JF (1986). The inheritance of Gilles de la Tourette's syndrome and associated behaviors. Evidence for autosomal dominant transmission. New England Journal of Medicine 315, 993-997.
32. Pauls DL, Towbin KE, Leckman JF, Zahner GE, Cohen DJ (1986). Gilles de la Tourette's syndrome and obsessive-compulsive disorder. Evidence supporting a genetic relationship. Archives of General Psychiatry 43, 1180-1182.
33. 18F]FDG PET study in obsessive-compulsive disorder. A clinical/ metabolic correlation study after treatment. British Journal of Psychiatry 166, 244-250.
34. Pigott TA, Hill JL, Grady TA, L'Heureux F, Bernstein S, Rubenstein CS, Murphy DL (1993). A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP. Biological Psychiatry 33, 3-14.
35. 18F]altanserin-PET and the bolus/infusion approach. Journal of Cerebral Blood Flow Metabolism 23, 985-996.
36. 2A receptors is unaltered after citalopram and pindolol challenge. Journal of Cerebral Blood Flow Metabolism 24, 1037-1045.
37. Rauch SL, Jenike MA, Alpert NM, Baer L, Breiter HC, Savage CR, Fischman AJ (1994). Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Archives of General Psychiatry 51, 62-70.
38. Ravindran AV, Lapierre YD, Anisman H (1999). Obsessive-compulsive spectrum disorders: effective treatment with paroxetine. Canadian Journal of Psychiatry 44, 805-807.
39. Rosier A, Dupont P, Peuskens J, Bormans G, Vandenberghe R, Maes M, Grott T, Schiepers C, Verbuggen A, Mortelmans L (1996). Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging. Psychiatry Research 68, 11-22.
40. Saxena S, Brody AL, Ho ML, Alborzian S, Ho MK, Maidment KM, Huang SC, Wu HM, Au SC, Baxter Jr. BL (2001). Cerebral metabolism in major depression and obsessive-compulsive disorder occurring separately and concurrently. Biological Psychiatry 50, 159-170.
41. Saxena S, Brody AL, Ho ML, Alborzian S, Maidment KM, Zohrabi N, Ho KM, Huang SC, Wu HM, Baxter Jr. BL (2002). Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. Archives of General Psychiatry 59, 250-261.
42. Saxena S, Brody AL, Maidment KM, Dunkin JJ, Colgan M, Alborzian S, Phelps ME, Baxter Jr. BL (1999). Localized orbito-frontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 21, 683-93.
43. Schwartz JM, Stoessel PW, Baxter Jr. LR, Martin KM, Phelps ME (1996). Systematic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. Archives of General Psychiatry 53, 109-113.
44. Sheline YI, Mintun MA, Moerlein SM, Snyder AZ (2002). Greater loss of 5-HT(2A) receptors in midlife than in late life. American Journal of Psychiatry 159, 430-435.
45. Smith GS, Price JC, Lopresti BJ (1998). Test-retest variability of serotonin 5HT2A receptor binding measured with positron emission tomography and [18F]-Altanserin in the human brain. Synapse 30, 380-392.
46. Swedo SE, Pietrini P, Leonard HL, Schapiro MB, Rettew DC, Goldberger EL, Rapoport SI, Rapoport JL, Grady CL (1992). Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy. Archives of General Psychiatry 49, 690-694.
47. Swedo SE, Schapiro MB, Grady CL, Cheslow DL, Leonard HL, Kumar A, Friedland R, Rapoport SI, Rapoport JL (1989). Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Archives of General Psychiatry 46, 518-523.
48. Tan PZ, Baldwin RM, Van Dyck CH, Al-Tikriti M, Roth B, Khan N, Charney DS, Innis RB (1999). Characterization of radioactive metabolites of 5-HT2A receptor PET ligand. Nuclear Medicine and Biology 26, 601-608.
49. Talairach J, Tournoux P (1988). Co-Planar Stereotaxic Atlas of the Human Brain. Stuttgart, Germany: Georg Thieme Verlag.
50. Weissman MM, Bland RC, Canino GJ, Greenwald S, Hwu HG, Lee CK, Newman SC, Oakley-Browne MA, Rubio-Stipec M, Wickramaratne PJ, Wittchen HC, Yeh EK (1994). The cross national epidemiology of obsessive-compulsive disorder. The Cross National Collaborative Group. Journal of Clinical Psychiatry 55 (Suppl.), 5-10.
51. WHO (1992-1994). ICD-20: International Statistical Classification of Diseases and Related Health Problems: 10th Revision. Geneva: World Health Organization.
52. Zohar J, Judge R (1996). Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. British Journal of Psychiatry 169, 468-74.